News
Stay up to date with CellCentric and follow us on Twitter
Key information, updates and news can be found through our tweets
We’ll be at ASH24, sharing latest Phase II clinical data on our oral small molecule p300/CBP inhibitor, inobrodib. See: https://www.cellcentric.com/press-release/cellcentric-to-share-latest-inobrodib-phase-ii-data-oral-presentation-at-ash-2024/
We’ll be at #ASH24. Presentation on our novel MoA oral drug, to treat multiple myeloma. See: https://www.cellcentric.com/press-release/cellcentric-to-share-latest-inobrodib-phase-ii-data-oral-presentation-at-ash-2024/ Many thanks @DrEmmaSearle, The Christie NHS Fdn Trust.
We are delighted to collaborate with the American Cancer Society CAN, gaining insights on needs and preferences of people with multiple myeloma. @ACSCAN
We’ll be at ASH24, sharing latest Phase II clinical data on our oral small molecule p300/CBP inhibitor, inobrodib. See: https://www.cellcentric.com/press-release/cellcentric-to-share-latest-inobrodib-phase-ii-data-oral-presentation-at-ash-2024/
We’ll be at #ASH24. Presentation on our novel MoA oral drug, to treat multiple myeloma. See: https://www.cellcentric.com/press-release/cellcentric-to-share-latest-inobrodib-phase-ii-data-oral-presentation-at-ash-2024/ Many thanks @DrEmmaSearle, The Christie NHS Fdn Trust.
We are delighted to collaborate with the American Cancer Society CAN, gaining insights on needs and preferences of people with multiple myeloma. @ACSCAN
We’ll be at #ASH24, San Diego, Dec 7-10. Sharing latest Phase II clinical data on our pioneering p300/CBP oral inhibitor drug, inobrodib.
Karen and Debbie are in Rio for #IMS24. Our novel oral drug for R/R multiple myeloma is in Phase II trials. #MMSM #multiplemyeloma
Beyond and alongside antibody-based therapies for multiple myeloma, there is a need for novel oral agents, that can be taken in the community.
We’ll be at ASH24, sharing latest Phase II clinical data on our oral small molecule p300/CBP inhibitor, inobrodib. See: https://www.cellcentric.com/press-release/cellcentric-to-share-latest-inobrodib-phase-ii-data-oral-presentation-at-ash-2024/
We’ll be at #ASH24. Presentation on our novel MoA oral drug, to treat multiple myeloma. See: https://www.cellcentric.com/press-release/cellcentric-to-share-latest-inobrodib-phase-ii-data-oral-presentation-at-ash-2024/ Many thanks @DrEmmaSearle, The Christie NHS Fdn Trust.
We are delighted to collaborate with the American Cancer Society CAN, gaining insights on needs and preferences of people with multiple myeloma. @ACSCAN
We’ll be at #ASH24, San Diego, Dec 7-10. Sharing latest Phase II clinical data on our pioneering p300/CBP oral inhibitor drug, inobrodib.
Karen and Debbie are in Rio for #IMS24. Our novel oral drug for R/R multiple myeloma is in Phase II trials. #MMSM #multiplemyeloma
Beyond and alongside antibody-based therapies for multiple myeloma, there is a need for novel oral agents, that can be taken in the community.
We’ll be at ASH24, sharing latest Phase II clinical data on our oral small molecule p300/CBP inhibitor, inobrodib. See: https://www.cellcentric.com/press-release/cellcentric-to-share-latest-inobrodib-phase-ii-data-oral-presentation-at-ash-2024/
We’ll be at #ASH24. Presentation on our novel MoA oral drug, to treat multiple myeloma. See: https://www.cellcentric.com/press-release/cellcentric-to-share-latest-inobrodib-phase-ii-data-oral-presentation-at-ash-2024/ Many thanks @DrEmmaSearle, The Christie NHS Fdn Trust.
We are delighted to collaborate with the American Cancer Society CAN, gaining insights on needs and preferences of people with multiple myeloma. @ACSCAN
We’ll be at #ASH24, San Diego, Dec 7-10. Sharing latest Phase II clinical data on our pioneering p300/CBP oral inhibitor drug, inobrodib.
Karen and Debbie are in Rio for #IMS24. Our novel oral drug for R/R multiple myeloma is in Phase II trials. #MMSM #multiplemyeloma
Beyond and alongside antibody-based therapies for multiple myeloma, there is a need for novel oral agents, that can be taken in the community.
Latest press releases
